Doctors may soon have a powerful new tool to match patients with the most effective blood pressure treatments. Built on data from hundreds of trials, it could transform care for millions living with hypertension.
A new online calculator could transform the treatment of high blood pressure by helping doctors select the most effective medications based on evidence from nearly 500 clinical trials.
A first-of-its-kind Blood Pressure Treatment Efficacy Calculator built on data from nearly 500 randomised clinical trials in over 100,000 people allows doctors to see by how much different medications are likely to lower blood pressure.
The research could transform how the condition is managed, allowing doctors to choose a treatment for each patient based on the degree to which they need to lower their blood pressure.
“This is really important because every 1mmHg reduction in systolic blood pressure lowers your risk of heart attack or stroke by two percent,” said Nelson Wang, cardiologist and Research Fellow at The George Institute for Global Health.
“But with dozens of drugs, multiple doses per drug, and most patients needing two or more drugs, there are literally thousands of possible options, and no easy way to work out how effective they are,” he said.
The new tool helps overcome this challenge by calculating the average treatment effect seen across hundreds of trials. It also categorises treatments as low, moderate, and high intensity, based on how much they lower blood pressure (BP) — an approach already routinely used in cholesterol lowering treatment.
A single antihypertensive medication - still the most common way treatment is started — typically lowers systolic BP by just 8-9 mmHg, while most patients need reductions of 15-30 mmHg to reach ideal targets.
Dr Wang explained that while the traditional way of doing this is by measuring blood pressure directly for each patient and adjusting treatment accordingly, in fact BP readings are far too variable, or ‘noisy’, for it to be reliable.
“Blood pressure changes from moment to moment, day to day and by season — these random fluctuations can easily be as big or larger than the changes brought about by treatment,” he said.
“Also, measurement practices are often not perfect, bringing in an additional source of uncertainty — this means it’s very hard to reliably assess how well a medicine is working just by taking repeated measurements.”
Anthony Rodgers, Senior Professorial Fellow at The George Institute for Global Health, said that while hypertension, or high blood pressure, is the most common reason people visit their doctor, there has been no single, up-to-date resource to show how effective different blood pressure medications are — especially when used in combination or at varying doses.
“Using the calculator challenges the traditional ‘start low, go slow, measure and judge’ approach to treatment, which comes with the high probability of being misled by BP readings, inertia setting in or the burden on patients being too much,” he said.
“With this new method you specify how much you need to lower blood pressure, choose an ideal treatment plan to achieve that based on the evidence, and get the patient started on that ideally sooner rather than later.”
The next step is to test this new approach in a clinical trial, where patients will be prescribed treatments based on how much they need to lower their blood pressure, guided by the calculator.
High blood pressure is one of the world’s biggest health challenges, affecting as many as 1.3 billion people and leading to around ten million deaths each year.
Often called a silent killer as it does not cause any symptoms on its own, it can remain hidden until it leads to a heart attack, stroke or kidney disease. Fewer than one in five people with hypertension have it under control.
“Given the enormous scale of this challenge, even modest improvements will have a large public health impact — increasing the percentage of people whose hypertension is under control globally to just 50 % could save many millions of lives,” Professor Rodgers added.
Original Article: Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and metaanalysis of randomised, double-blind, placebo-controlled trials; The Lancet; DOI:10.1016/S0140-6736(25)00991-2
Date: 08.12.2025
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.